

Access to a mix of live  
and on-demand content

Strategy,  
investment &  
networking

# LSX | NORDIC CONGRESS VIRTUAL

STRATEGY, INVESTMENT, PARTNERING  
AND DEAL MAKING FOR LIFE SCIENCE  
EXECUTIVE LEADERS

Thought  
leadership  
opportunities

Live and  
on-demand  
panels

3rd Annual Conference

1-4 September 2020

Created by

**LSX** | The network  
for life science  
executive leaders

[www.lsxleaders.com/nordic](http://www.lsxleaders.com/nordic)  
#lsxnordic @lsxleaders

# LSX Nordic Congress Virtual

## What is it and who is it for?



The LSX Nordic Congress is a high-calibre, senior executive conference and partnering event designed to bring international investment and strategic partners for Nordic life companies to the region. The Nordic region has long produced world-leading science and innovation and the LSX Nordic Congress will be all about showcasing this innovation, both of the region's industry leaders but also through start-ups and technology innovators driving the future of healthcare.

Now in its third year, and delivered digitally, the online experience features everything from the physical event and more! Hear from, connect, network and schedule 1:1 meetings with the leading lights and most exciting startups in life sciences from across the Nordics, as well as global investors and partners!

## What is a virtual experience?

Social distancing practices around the world have shown just how productive digital work methods can be, and we are confident LSX Nordic Congress Virtual will deliver equal if not even greater, value as attending the physical event.

Across four days you'll be able to:

- Access a mixture of live interactive panels and on-demand debates and discussions; dip in and out of the content sessions and watch at times that suit your partnering schedules so you never miss a thing.
- Schedule and take 1:1 video meetings and network with hundreds of Nordic life science executives, global and investors and partners from the comfort of your office or home workspace.
- Participate in live interactive forums with your peers and expert-led workshops!
- Dive into an exciting library of company showcases from the most innovative life sciences companies and budding startups

Don't just think of it as an online physical event, think of it as a brand-new virtual experience!

LSX Nordic Congress Virtual offers three different content formats in which enjoy the sessions on offer:

**LIVE** = Real-time content with audience Q&A (becomes on-demand once held)

**ON-DEMAND** = Evergreen content that can be watched anytime to fit around your schedule

**INTERACTIVE** = Live, peer-to-peer grouped sessions allowing multi-way discussion

# Congress Partners

## Host Sponsor



## Gold Sponsors



## Silver Sponsors




## Bronze Sponsors


## Associate Partners



## Media & Supporting Partners



# Key Speakers



**Renée Aguiar-Lucander**  
CEO, Calliditas Therapeutics



**Ingrid Akay**  
Managing Partner  
Hadean Ventures



**Sascha Alilovic**  
Partner, SHS



**Martin Åmark**  
CEO, Xbrane Biopharma



**Karl Bergman**  
CEO, Elypta



**Mats Berggren**  
Director, Digital Business Innovation & External Collaboration Models, M-Digital Lead, Merck KGaA



**Carsten Borring**  
AVP, Listings EMEA and Head of Listings & Capital Markets, NASDAQ



**Stephan Christgau**  
Partner, Eir Ventures



**Don deBethizy**  
Director, Argenx



**Magnus Corfitzen**  
CEO, Ascelia Pharma



**Ingaliil Hyltander**  
Commercial Operation Director Pharma Scandinavia, Bayer



**Andreas Jurgeit**  
Partner, Lundbeckfonden



**Carsten Kjær Joensen**  
Head of Office for Life Sciences, Government Offices of Denmark



**Adam Kostyál**  
SVP, Nasdaq



**Thierry Laugel**  
Managing Partner Kurma Partners



**Phil L'Hullier**  
Head of BD, Europe, European Innovation Hub MSD



**Gunilla Osswald**  
CEO, BioArctic



**Ulrica Slåne Bjerke**  
CIO, Arctic Aurora LifeScience



**Patrik Sobocki**  
Investment Manager Industrifonden



**Nikolaj Sørensen**  
CEO, Orexo



**Klaus Stöckemann**  
Managing Partner Peppermint Venture Partners



**Maria Tell**  
Investment Manager, Almi Invest



**Karl Xavier**  
Partner Axilium Capital



**Jenni Nordborg**  
Head of the Office for Life Sciences, Government Offices Sweden



**Thomas Lönngren**  
Strategy Advisor, NDA Group and former Head of EMA



# Agenda at a glance

## Day 1

09:00	ON-DEMAND SHOWCASES (available all-day)
09:05	LIVE: KEYNOTE ADDRESS-THE FUTURE OF DANISH LIFE SCIENCES STRATEGY
09:20	LIVE: KEYNOTE ADDRESS - THE FUTURE OF SWEDISH LIFE SCIENCES STRATEGY
09:35	LIVE: JOINT Q&A
10:00	LIVE: OPENING PANEL:CULTIVATING A SUSTAINABLE ECOSYSTEM AND COMPANIES WITH LONG-TERM AMBITIONS IN THE NORDICS
10:30	1:1 PARTNERING (available all-day)
11:00	ON DEMAND KEYNOTE PANEL: INVESTING IN HEALTHTECH & DIGITAL HEALTH - THE NEXT WAVE OF NORDIC INNOVATION
11:00	LIVE: PUBLIC CEO FORUM
13:00	ON DEMAND PANEL: WHAT'S HOT IN EARLY STAGE INVESTMENT?
14:00	LIVE: PRIVATE CEO FORUM (1 hr 45 mins)
16:00	LIVE PANEL: GLOBAL SYNDICATION AND EXPANDING YOUR INTERNATIONAL INVESTOR BASE
16:45	CLOSE

## Day 2

09:15	LIVE KEYNOTE PANEL: COMING OUT THE OTHER SIDE: PERSPECTIVES ON LIFE SCIENCE STRATEGIES, PRIVATE AND PUBLIC FINANCING, PARTNERSHIPS AND M&A IN THE AFTERMATH POST-COVID-19
10:00	1:1 PARTNERING (available all-day)
10:15	PRESENTATION: DEVELOPMENT WITH THE END IN MIND - HOW TO BRIDGE THE "VALLEY OF DEATH"
12:45	DRIVING SHAREHOLDER VALUE THROUGH EFFECTIVE PARTNERSHIPS
15:00	LIVE: DEVELOPING AND OPTIMISING PHARMA PARTNERSHIPS ACROSS BIOTECH, MEDTECH AND HEALTHTECH INNOVATION
16:00	LIVE: DEVELOPING AND OPTIMISING PHARMA PARTNERSHIPS ACROSS BIOTECH, MEDTECH AND HEALTHTECH INNOVATION
16:45	CLOSE

## Day 3

09:00	ON DEMAND: ALL PANELS (available all-day)
09:00	ON-DEMAND SHOWCASES (available all-day)
09:00	1:1 PARTNERING (available all-day)

## Day 4

09:00	ON DEMAND: ALL PANELS (available all-day)
09:00	ON-DEMAND SHOWCASES (available all-day)
09:00	1:1 PARTNERING (available all-day)

\*All times in CEST (GMT - 1hr)

\*All times in CEST (GMT - 1hr)

# 2020 Investors & Pharma BD



# 2020 Investors & Pharma BD



# Pre-Day IPO Bootcamp

In line with our mission to support funding, financing and deal making in the sector, LSX teaming up with some of the regions foremost experts, advisers, bankers and consultants to help CEOs and CFOs navigate the how, what, where and when of a successful IPO on Nasdaq Nordics. The Bootcamp runs as part of the 3rd annual LSX Nordic Congress, delivered virtually.

The Nordic IPO Bootcamp is an invitation only online forum, workshop, and series of digital 1-2-1 video meetings. It provides CEOs and CFOs of life science companies contemplating an IPO a unique opportunity to come together for a series of frank and open discussions with peers, case studies from executives who have recently been through the process, and for tailored and 1-2-1 advice with the region's foremost experts, advisers, bankers and consultants.

Co-hosted by:



09:00

**LIVE: THE CURRENT STATE OF THE NORDIC IPO MARKET**

09:20

**LIVE ROUNDTABLE: DETERMINING AND DEFINING YOUR IPO STRATEGY**

10:00

**IPO CASE STUDY**

Magnus Corfitzen, *CEO, Ascelia Pharma*

11:00

**1:1 EXPERT CONSULTATIONS: OVER ZOOM CALLS**

17:00

**CLOSE**

\*Bootcamp by invitation only. If you are interested in a seat at the bootcamp message [Josh@lsxleaders.com](mailto:Josh@lsxleaders.com)

\*All times in CEST (GMT - 1hr)

# Full Agenda

## Conference - 1 September

09:00

**LSX & Nasdaq Welcome**

Josh Dance, *SVP, LSX*  
Adam Kostyál, *SVP, Nasdaq*

09:05

**LIVE: Keynote Address – The Future of Danish Life Science Strategy**

- Providing an update on the 2018 Life Sciences Growth Plan
- Progress on the 36 initiatives put in place to target barriers and capitalise on opportunities across the value chain for the Danish Life Sciences Industry across the value chain
- How and in what ways has the covid-19 pandemic affected the sector?

Carsten Kjær Joensen, *Head of the Office for Life Sciences, Government Offices of Denmark*

09:20

**LIVE: Keynote Address – The Future of Swedish Life Science Strategy**

- Outlining the core components of the new Life Sciences Strategy
- How will Sweden work to attract and maintain life science companies and strengthen home-grown companies' abilities to grow and meet global healthcare demands?
- How and in what ways will the new strategy and roadmap be implemented?

Jenni Nordborg, *Head of the Office for Life Sciences, Government Offices of Sweden*

09:35

**LIVE: Joint Q&A**

Carsten Kjær Joensen, *Head of the Office for Life Sciences, Government Offices of Denmark*  
Jenni Nordborg, *Head of the Office for Life Sciences, Government Offices of Sweden*  
Josh Dance, *SVP, LSX*

10:00

**LIVE: Opening Panel: Cultivating a sustainable ecosystem and companies with long-term ambitions in the Nordics**

*Key stakeholders from across the region discuss how the Nordic ecosystem is evolving and what more can be done to finance, invest and build the Nordic cluster with a great proportion of larger companies with long-term ambitions, to complement and support the thriving startup and growth stage community.*

- What does it take to build large and internationally competitive companies? Do enough have the long-term ambitions?
- Which policy, regulation and industry initiatives can help build upon the exceptional life science leadership and innovation and work towards an even more internationally competitive hub and the growth of \$billion businesses?
- How, and in which ways, can Government strategy and support help shape and build the Nordic life sciences cluster?
- What are the key success factors for companies in internationalisation and finding global investors, partners and advisors?

Moderator: Bobby Soni, *CBO, Novo Nordisk BII*  
Nikolaj Sørensen, *CEO, Orexo*  
Magnus Corfitzen, *CEO, Ascelia Pharma*  
Jenni Nordborg, *Head of the Office for Life Sciences, Government Offices of Sweden*  
Adam Kostyál, *SVP, Nasdaq*

11:00

**Keynote Panel: Investing in Healthtech & Digital Health - The next wave of Nordic innovation**

*Healthtech and digital health technologies are starting to realise their promise and make meaningful impacts across the life science and healthcare space, and the Nordic countries are among Europe's leaders in the digital healthcare revolution. Investors and executives discuss the local and international investment landscape in digital and health technology and how the Nordics can lead the way in innovation.*

- How quickly could Nordic healthtech innovation grow to match medtech and biotech expertise?
- The region already boasts some exciting digital health success stories; is innovation in this area continuing to grow and how are investors seeing digital investment opportunities compared to more traditional investments?
- The covid-19 epidemic has expedited the digitisation the healthcare sector and validated its necessity; how are investors evaluating these opportunities as necessity in which specific technologies has the acceleration been most evident, and how do you pick the future winners?

Moderator: Kathrine Myhre, *CEO, Norway Health Tech*  
Patrik Sobocki, *Investment Manager, Industrifonden*  
Klaus Stöckemann, *Managing Partner, Peppermint VP*  
Andreas Lindblom, *CEO, Sietty*

11:00

**LIVE: Public CEO Forum (Zoom)**

Co-hosted by:



Moderator:  
Don deBethizy, *Director, Argenx*

Nordic and Global Capital Market Outlook  
Adam Kostyal, *SVP, Head of European Listings, Nasdaq*  
Peter Legind-Hansen, *MD, Nasdaq*

# Full Agenda

## Conference - 1 September

11:00	<div><div>LIVE: Public CEO Forum (Zoom)</div><div>Co-hosted by:</div><div><div></div><div></div></div><div><div>Key Legal Trends and Highlights</div><div>Erik Sjöman, <i>Partner</i>, Vinge</div><div>Dain Härd Nevenon, <i>Partner</i>, Vinge</div></div><div><div>Biotech Going Digital</div><div>Nikolaj Sørensen, <i>CEO</i>, Orexo</div></div></div>
13:00	<div><div>What's hot in early stage investment?</div><div>Expert early-stage investors highlight where they see the exciting and hot new areas in life sciences investment. They will also debate how smaller can compete with larger funds dominating increasingly larger series A rounds, and if we see an even greater focus on early syndication from smaller players, particularly post-covid.</div><div><div><div>• The Nordic early-stage startup ecosystem is booming—in which areas is there most excited and where is the early capital currently going?</div><div>• How are smaller funds competing with larger local and international funds? Will we see ever greater syndication in early deals?</div><div>• Is there enough support and local capital for early-stage innovation to be funded and thrive?</div></div></div><div><div>Karl Xavier, <i>Partner</i>, Axilium Capital</div><div>Andreas Jurgeit, <i>Partner</i>, Lundbeckfonden Emerge</div><div>Ingrid Akay, <i>Managing Partner</i>, Hadean Ventures</div><div>Maria Tell, <i>Investment Manager</i>, Life Sciences, Almi Invest</div></div></div>
14:00	<div><div>LIVE: Private CEO Forum (Zoom)</div><div>Co-hosted by:</div><div><div></div><div></div></div><div><div>Case Studies</div><div><div>Nordic and Global Capital Market Outlook</div><div>Adam Kostyal, <i>SVP</i>, <i>Head of European Listings</i>, Nasdaq</div><div>Peter Legind-Hansen, <i>MD</i>, Nasdaq</div></div><div><div>Accessing US Capital &amp; Partners</div><div>Chris Jeffers, <i>Member</i>, Mintz</div></div><div><div>Raising Capital During COVID-19</div><div>Patric Stenberg, <i>CEO</i>, Gesynta</div></div></div></div>
16:00	<div><div>LIVE: Panel: Global syndication and expanding your international investor base</div><div>With new Nordic and European life science funds emerging, long term specialists recharging and new players and capital from Asia and the Middle East, as well as the US, increasingly entering into deals, global syndication in the healthcare space is reforming the investment landscape. Investors discuss how the Nordic region, as a leading European hub for new science and innovation, and the companies from it can access, build and leverage an international investor base.</div><div><div><div>• Will the trend of private rounds in place of IPOs in Europe for European companies continue? Do the strong Nordic public markets factor into investment decisions?</div><div>• Will increasing interest from American and Asian funds lead to more competitive tension for deals in Europe?</div><div>• How can companies, and how will investors, be getting out and connecting internationally in the new normal?</div></div></div><div><div>Moderator: John Rudy, <i>Member</i>, Mintz</div><div>Stephan Christgau, <i>Partner</i>, Eir Ventures</div><div>Rachel Mears, <i>Partner</i>, Jeito</div><div>Thierry Laugel, <i>Managing Partner</i>, Kurma Partners</div><div>Sascha Alilovic, <i>Managing Partner</i>, SHS</div><div>Petros Farah, <i>Vice President</i>, Vickers Venture Partners</div></div></div>
16:45	<div><div>Close of Day 1 &amp; Virtual Drinks - Partnering Continues</div></div>

# Full Agenda

## Conference - 2 September

09:15	<div><div>LIVE: Keynote Panel: Coming out the other side: Perspectives on life science strategies, private and public financing partnerships and M&amp;A in the aftermath post-Covid-19</div><div>The COVID-19 outbreak has sent shockwaves through the world, disrupting every industry and creating uncertainties in financial markets. The life sciences and healthcare is in a unique position with some companies pivoting to help in the fight against the virus, others business plans being severely disrupted, and both public and private investors in the sector navigating an untrodden path. A cross-stakeholder panel discusses</div><div><div><div>• What has been the impact on investors portfolio companies, investment strategies and appetite in the short and medium term?</div><div>• How and where will changes in the public and private capital available to companies affect wider industry M&amp;A activity?</div><div>• Could Pharma partnering strategies change? How can companies best position themselves to come out stronger?</div></div></div><div><div>Moderator: Chris Maggos, <i>Managing Director</i>, <i>Head of Europe</i>, LifeSci Advisors</div><div>Ulrica Slåne Bjerke, <i>CIO</i>, Arctic Aurora LifeScience</div><div>Benedicte Bakke, <i>Portfolio Manager</i>, DNB Asset Management</div><div>Søren Møller, <i>Managing Director</i>, Novo Seeds</div><div>Mario Augusto Maia, <i>Head of Investments</i>, Novozymes</div></div></div>
10:15	<div><div>Presentation: Development with the end in mind - how to bridge the “valley of death”</div><div><div><div>• Common threats for a startups and how to mitigate them</div><div>• Developing an integrated strategy for efficient pharmaceutical development</div><div>• Strategies to bridge the valley of death</div></div></div><div><div>Anders Nyholm, <i>Director Life Science Consulting</i>, ProPharma Group</div></div></div>
12:45	<div><div>Driving shareholder value through effective partnerships</div><div>Partnering up with big pharma or other life science companies can make cost savings and pool resources and expertise, but for public companies are not without risk. Executives of public companies with licencing, co-development and R&amp;D partnerships share their stories of securing these deals and discuss effective deal structures, mitigating risks in asset dilution and commercialisation rights and how to drive shareholder value through optimising these partnerships.</div><div><div><div>• Balancing partnerships with further capital raises for pipeline development; what are the long term affects on stock price?</div><div>• What are the most effective deal structures for public companies entering partnerships?</div><div>• How can you ensure deals are transformative for company growth whilst retaining value for shareholders?</div></div></div><div><div>Moderator: Jan de Kerpel, <i>Managing Director</i>, Kempen</div><div>Gunilla Osswald, <i>CEO</i>, BioArctic</div><div>Don deBethizy, <i>Director</i>, Argenx</div><div>Renée Aguiar-Lucander, <i>CEO</i>, Calliditas Therapeutics</div></div></div>
15:00	<div><div>LIVE: Nasdaq Nordic listing and cross trading on the US OTC Markets: Creating a global trading solution for investors and opportunity for Nordic companies</div><div>Reaching American investors is usually always a big focus for life sciences companies, be that for private or public investments. What are the best strategies for gaining access and exposure to American capital? The panel discusses:</div><div><div><div>• When should a company consider cross-trading on the US OTC Markets?</div><div>• How does OTC Markets and Nasdaq Nordics businesses complement each other and what does this mean for Nordic issuers?</div><div>• What are the benefits of gaining access and exposure to American investors through the secondary US OTC market?</div><div>• From the company perspective, what can this exposure mean for your business? How can cross trading increase volume and liquidity on the local exchange due to greater access to US investors?</div></div></div><div><div>Moderator: Joe Coveney, <i>Vice President</i>, OTC Markets</div><div>Lena Wange, <i>Head of Investor Relations</i>, Orexo</div><div>Adam Kostyal, <i>SVP</i>, Nasdaq</div></div></div>
16:00	<div><div>LIVE: Developing and optimising pharma partnerships across biotech, medtech and healthtech innovation</div><div>The potentially transformative nature of partnership a big pharma is well documented but is not without its risks and challenges and partnerships and deals differ between private and public companies. Pharma continue to be hungry to source innovation and build win-win partnerships with the latest technologies to supplement and complement internal R&amp;D. Heads of innovation, search and evaluation and business development from big Pharma discuss the role pharma companies are taking in supporting younger companies and the evolving strategies in all life science and technology partnerships and deals.</div><div><div><div>• Will the trend of private rounds in place of IPOs in Europe for European companies continue?</div><div>• Will increasing interest from American and Asian funds lead to more competitive tension for deals in Europe?</div><div>• How can companies, and how will investors, be getting out and connecting internationally in the new normal?</div></div></div><div><div>Moderator: Thomas Lönngren, <i>Strategy Advisor</i>, NDA Group and former Head of EMA</div><div>Phil L’Huillier, <i>Head of BD</i>, <i>Europe</i>, <i>European Innovation Hub</i>, MSD</div><div>Ingalill Hylltander, <i>Commercial Operation Director</i> <i>Pharma Scandinavia</i>, Bayer</div><div>Mats Berggren, <i>Director</i>, <i>Digital Business Innovation &amp; External Collaboration Models</i>, M-Digital Lead, Merck KGaA</div><div>Nerida Scott, <i>Head of Johnson &amp; Johnson Innovation EMEA</i>, Johnson &amp; Johnson</div></div></div>
16:45	<div><div>Close of Day 2 Content - Partnering Continues</div></div>



# Full Agenda

## Conference - 3 September

To maximise the opportunity for international 1:1 partnering in the virtual format, across multiple timezones and working around work commitments and schedules, the event and partnering system will remain live for the full week! What’s more, to ensure you have the chance to view all of the panel discussions, keynote sessions and showcases of the most exciting and innovative companies the Nordic region has to offer, these will all be available on-demand for the rest of the week too!

ALL DAY	All live and on-demand panels available on-demand	1:1 Partnering (All Day)	On Demand Showcase Videos (All Day)
---------	---	--------------------------	-------------------------------------

## Conference - 4 September

ALL DAY	All live and on-demand panels available on-demand	1:1 Partnering (All Day)	On Demand Showcase Videos (All Day)
---------	---	--------------------------	-------------------------------------

# Showcases

The virtual experience showcases all stages of private and public biotech, medtech and healthtech companies from across the Nordic Region.

Companies have the opportunity to pre-record and release on-demand video showcases alongside their profiles and relevant supporting documentation for investors and partners to search, evaluate and connect. Showcases will remain available on-demand for the full four-day experience.

Companies have the opportunity to utilise a virtual booth to stream / broadcast additional content that sits along side live chat functionality to help demonstrate products/technology in realtime.

When is showcasing and a virtual tech booth a good idea:

- When you are actively fundraising or looking to attract partners
- When you have impactful company or product news
- When you are raising awareness of your business or new developments in your pipeline or commercial development



# Confirmed Showcases



# 1:1 Partnering


LSX is committed to foster collaboration among all virtual conference attendees. Our goal is for you to establish new partnerships, and find the best connections possible even when face-to-face is not possible.

Video and audio-enabled partnering is delivered through this web-based content platform which allows the pre-arrangement of video-conference meetings 2 weeks from the event and for the duration of the four days.

Swapcard is an powerful AI-driven matchmaking platform, meaning the stress of finding likeminded executives is removed when using this automated software. Complete your profile in full and Swapcard will AI-match with registered delegates, presenting you with a rated list of executives aligned to your search criteria from most relevant to least relevant. You can still search the full list of participants alongside this automated process should you wish to expand your outreach to other profiles.

Registered attendees will be able to access their own personal schedule, search attendees' profiles, request and reschedule meetings with other executives and connect for private and secure 20min video conferencing. 1:1 Partnering runs 24hrs to accommodate all time zones and kicks off from 10am CET on Day 1.


We also realise that some of the most valuable connections happen through serendipitous and chance meetings. For this reason there will be several dedicated networking receptions built in to the virtual schedule each day allowing you to engage in live text chat or 3min speed networking-style video calls with other online attendees, before deciding if you'd like to arrange a more formal meeting through the partnering system.




# 2019 Attendee Breakdown

The LSX Nordic Congress grow significantly in the second year, in terms of the overall numbers and diversity of the delegation, the international investor attendance, and with a showcase of some of the most exciting life science and healthcare companies the region has to offer; from the newest innovative start-ups to the region's leading public corporates.

These stats highlight the diversity of the audience.




# 2019 Companies Breakdown





# 2019 Investor Breakdown



# 2019 Attendee Summary

Chief Executive Officer, 2A Pharma  
Chief Business Officer, 2cureX  
Chief Operating Officer, 2N Pharma  
Partner, 4BIO Capital  
Investment Director, 4BIO Capital  
CEO, AIM Pharma  
COO, Aasa Health AB - "Träning på Recept"  
Partner, ABG Sundial Colliar  
CEO, Ably  
CEO, Abomics  
CEO, Active Biotech  
Angel, Activebiz  
CEO, AddBIO  
Chairman, AddBIO  
Partner, Advokatfirman Delphi  
CEO, Affibody  
CEO, Age Labs  
Investment Manager, Almi Invest  
Senior Financial Advisors, Alpha Blue Ocean  
Chief Executive Officer, Annexin Pharmaceuticals  
CSO, Anocca  
Chief Executive Officer & Scientific Founder, Anocca  
CEO, Aplagon  
CEO, Apoglyx  
Founder, PM, Arctic  
Chief Executive Officer, Arocell  
Chief Executive Officer, Ascelia Pharma  
Founder and CEO, Asgard Therapeutics  
CEO, Atrogi  
CFO, Avia Pharma  
Partner European Patent Attorney, AWA Sweden  
CEO, AZ BioVentureHub  
Founding Partner, Bedrock  
CEO, BerGenBio  
COO, Biomedical Bonding  
CEO, Biomedical Bonding  
CEO, Biomedics  
CEO, Bioservo Technologies  
CEO / EDITOR, BioStock  
CEO, BrainCool  
Principal, Bridge Valley Ventures  
CEO, Calliditas Therapeutics  
Chief Executive Officer, Cantargia  
CEO, Cardiacs  
Director, Business Development, Celerion  
Co founder + CFO, Cerenion  
CEO, Cerenio Scientific  
Director of Business Development, Clinical Reserach Services Turku-CRST  
CEO, CLS  
project manager, Connect Uppsala  
Client Partner, Coulter Partners  
CEO, Cytovac  
CEO, Desentum  
President & CEO, Diamyd Medical  
CFO, Diamyd Medical  
CEO, Dicot  
Board Member, Dicot  
CEO, Dilafor  
Chief Commercial Officer, Dyadic International  
Chief Executive Officer, Elypta  
CEO, Endovascular Development  
Managing Director, EstBAN  
CEO, EVM  
Partner, Head of Corporate Finance and Life Sciences Nordics, EY  
Partner, EY  
VP, Financing and Investor Relations, Faron Pharmaceuticals  
Associate, Forbion  
CEO, Gedea Biotech  
CEO, Genagon Therapeutics  
Chief Operating Officer, Genagon Therapeutics  
Senior Investment Manager / Vice President Business Development, Global Core Medical  
Chief Executive Officer, GlucoSet  
National Coordinator Life Sciences, Government Offices of Sweden  
Digital Media Director, Guided Solutions  
CEO, Guided Solutions  
Managing Partner, Hadean Ventures  
Partner, Hadean Ventures  
Partner, HBM Partners  
Partner, HealthCap  
Investment Associate, HealthCap  
Chief Executive Officer, Herantis Pharma Plc  
Patent Director, HGF  
CEO, Hy5  
Associate, Illumina Ventures  
CEO, Immunicum  
Chief Executive Officer, Immunovia  
CEO, Immunscape  
Investment Manager, Industrifonden  
Venture investor, Industrifonden  
CEO, InfiCure Bio  
Director of Innovation, Innovation Skane  
CEO, Inorbit Therapeutics ab  
Investment Director, Inventure  
Investment Director, Investinor  
Senior Associate, Investinor  
Partner, IPF Partners  
Business Development Director, IQVIA  
Associate Director, IQVIA  
BD Director, IQVIA  
General Partner, Joint Polish Investment fund  
General Partner and Chairman, Julz  
Angel, Karolina Ventures  
Director, Kempen  
CEO, KIRAM  
Vice President, Kreos Capital  
Founder, Ktisis Bio  
Director, Lavivo  
CEO, Lavivo  
CEO, Lind Growth Strategy  
CEO, Longboat Amniotics  
Executive Vice President, LU Holding  
Portfolio Manager, LU Holding  
Consultant, LucyJRobertshaw  
Partner, Lundbeckfonden Emerge  
CEO, Lyfstone  
Partner, MAKI.VC  
CEO, Meabco

# 2019 Attendee Summary

CSO, Meabco  
CEO, Medbeat  
Chief Executive Officer, Medeon  
President, MedVASC  
Healthcare Reporter, Mergermarket  
Co-chair, Life Sciences Practice Group, Mintz Levin  
Cohn, Ferris, Glovsky and Popeo, P.C.  
CEO, Modus Therapeutics  
VD, Monica Hedberg Invest  
CEO, Monidor  
Executive Director, Oncology, MSD  
Investment Partner, MTIP  
European BD&L Manager, Mundipharma  
Senior Managing Director EMEA, Nasdaq  
Director, Nasdaq  
Strategy Advisor, NDA Group  
CEO, Nordic Nanovector  
Head of Communication, Norway Healthtech  
Managing Partner, Novo Seeds, Novo Holdings  
Associate, Novo Holdings  
VP of Search & Evaluation, Novo Nordisk  
CEO, Nuevolution  
CBO, deputy CEO, Oasmia Pharmaceuticals  
CEO, Ocusweep  
CEO, Omnio  
CEO & Founder, Oncology Venture  
Chief Operating Officer, Oncology Venture  
VP Business Development, Oncology Venture  
Chief Executive Officer, OnDosis  
Director, Optimum Strategic Communications  
Principal, Optum Ventures  
CEO, Otivio  
CEO, PanCryos  
CCO, Particle3D  
CEO, Particle3D  
CTO, Particle3D  
European Lead Worldwide Business Development, Pfizer  
Partner, Potter Clarkson  
Associate, Potter Clarkson  
Senior PPD Consulting Director, PPD  
Senior Account Director, PPD  
CFO, Primex Pharmaceuticals  
Group CEO, Primex Pharmaceuticals  
CEO, Prokarium  
Founder, R Ventures  
Chairman of the Board, Reccan Diagnostics  
EVP, Red Glead Discovery  
CEO, Resorbable Devices  
CEO, ResoTher Pharma ApS  
CEO, Respinor  
CBO & Deputy CEO, RhoVac  
PM, RhoVac  
Founding Director, Rigi Care  
CEO, SAGA Diagnostics  
Director, Finance, SAGA Diagnostics  
Chair, Board of Directors, Saniona  
CFO, Saniona

Partner, Sarsia Fund  
Managing Director, SBA Ltd (on behalf i2020 Accelerator)  
CEO, Scandion Oncology  
CEO, Sciety  
Investment Manager, Sciety  
Head of Equity Sales, Sedermera Fondkommission  
Chairman, Senzagen  
Chief Executive Officer, Senzagen  
Partner, Serendipity partners  
COO, Serodus ASA  
Chief Executive Officer, Serodus ASA  
Partner, SHS Capital  
Business Development, SmiLe Incubator  
Managing Partner, Sofinnova Partners  
CEO, Spago Nanomedical  
Programme and Partnerships Manager, Start Codon  
StartUp Health Ambassador, Europe & Israel, StartUp Health Inc  
Managing Director, Stifel  
CEO, Subcuject  
Managing General Partner, Sunstone Life Science Ventures  
CEO & Co-Founder, Surgify Medical  
PM, Swedbank Robur  
Chief Executive Officer, Swedish Orphan Biovitrum  
Head of Communications, Swedish Orphan Biovitrum  
Manager Swelife International, Swelife  
PA to CEO, Symphogen  
Chief Executive Officer, Symphogen  
Sr Director Business Development, Synteract  
Investment Manager, Tesi  
CEO, TFS  
Analyst, Tillväxtanalys  
Principal, Europe, TRINITY Life Sciences  
CEO, UmanSense  
Business coach, Umeå Biotech Incubator  
Angel, Uppsala Biotech  
Senior Advisor, Uppsala Innovation Centre  
CEO, Uppsala universitet Holding  
Investment director, Vækstfonden  
CBO, Valo Therapeutics  
Head of R&D, Valo Therapeutics  
Chief Operating Officer, VAR2 Pharmaceuticals  
Chief Executive Officer, Vetok  
CFO, Vicore Pharma  
Chief Executive Officer, Vicore Pharma  
Partner, Vinge  
Partner, Vinge  
Partner, Vitality in Aging Research Group  
Chief Executive Officer, Xbrane Biopharma  
Chief of innovation division, Zcube - Zambon research venture  
CEO, Zora Biosciences  
COO, Zora Biosciences

# Why Sponsor

The LSX Nordic Congress Virtual experience offers a limited number of opportunities for companies wishing to raise their profile, enhance their brand, demonstrate thought leadership and access and engage with leaders in Nordic life sciences and global investors and partners

**We are presenting tremendous opportunities for top tier service companies who would see the congress as a platform to:**

- Demonstrate thought leadership and position your organisation at the forefront of the exciting Nordic life sciences ecosystem
- Educate potential new clients and partners about your unique offering, service or solution
- Generate qualified business leads through bespoke, forums with high-calibre life science decision makers
- Be seen as an obvious partner of choice in your specified domain as this market grows

**What can sponsorship of a virtual experience offer that a physical event cannot?**

- Reporting and tracking; receive stats and intel on who and how many engaged with your session / content through the four-day experience and beyond
- Longer interaction and more impressions; the virtual experience gives an additional 30-days of exposure to all content, meaning your sessions / content reach a far wider audience than just those present the day the experience was live
- A larger geographical pool of prospects; there will always be time limitations as to how many delegates can attend a physical event, a virtual event is more accessible
- Halve your costs; removing flight, hotel and subsistence costs from your budget massively reduces your budgetary spend and saves you time meaning you are more productive

For sponsor or exhibition enquiries contact:

**Joe Knight, BD Manager,**  
**Joe@lsxleaders.com**  
**+44 (0) 20 7039 3408**



# Delegate Packages

## Pass Benefits

- Watch all the talks and panel discussions; Sessions are available to registered attendees live via an interactive experience and On-Demand
- Schedule 1:1 video partnering throughout the week with all attendees
- Join CEO Virtual Forums with your peers and workshops with industry experts
- The opportunity to record and deliver an online showcase to raise your company's profile
- Connect with attendees through live chat conversations
- Resources, reports and speaker presentations available for download

Industry Tickets	26-Jun	24-Jul	14-Aug	Full Price
Content Only Ticket	Free	Free	Free	Free
Investor Ticket + 1:1 Partnering	Free	Free	Free	2500
All...Tech Ticket + 1:1 Partnering	5000	6300	7600	8900
All...Tech Ticket + 1:1 Partnering + Showcase + Virtual Tech Demo Booth	8900	10100	11400	12700
Pharma Ticket + 1:1 Partnering	5000	6400	7600	8900
All Services Ticket + 1:1 Partnering	8900	10100	11400	12700

All prices are displayed in Swedish Krone (SEK).

For delegate enquiries contact:

Joe Knight, BD Manager,  
[joe@lsxleaders.com](mailto:joe@lsxleaders.com)  
+44 (0) 20 7039 3408

# Leading life science events



15-18 September 2020  
Virtual Event  
[www.lsxleaders.com/healthtech](http://www.lsxleaders.com/healthtech)



11-16 November 2020  
Virtual Event  
[www.lsxleaders.com/investival](http://www.lsxleaders.com/investival)



2-3 February 2021, 133 Houndsditch, London, UK  
[www.lsxleaders.com/world](http://www.lsxleaders.com/world)



2-3 February 2021, 133 Houndsditch, London, UK  
[www.lsxleaders.com/healthtech-leaders-2021](http://www.lsxleaders.com/healthtech-leaders-2021)



5-6 May 2021, Business Design Centre, London, UK  
[www.lsxleaders.com/healthspan](http://www.lsxleaders.com/healthspan)



5-6 May 2021, Business Design Centre, London, UK

Contact us today to find out how to get involved in any or all of our events.

[www.lsxleaders.com/events](http://www.lsxleaders.com/events)

# Contact Us

Strategy,  
investment &  
networking

For speaker opportunities contact:

**Josh Dance, SVP**  
[josh@lsxleaders.com](mailto:josh@lsxleaders.com)  
**+44 (0)20 7039 3403**

Thought  
leadership  
opportunities

For sponsor and booking opportunities contact:

**Joe Knight, BD Manager**  
[joe@lsxleaders.com](mailto:joe@lsxleaders.com)  
**+44 (0)20 7039 3408**

For press, media & marketing enquiries contact:

**Paul Gilbertson, Marketing Director**  
[paul@lsxleaders.com](mailto:paul@lsxleaders.com)  
**+44 (0)20 7039 3405**

Or visit us at  
**[www.lsxleaders.com/nordic](http://www.lsxleaders.com/nordic)**